1. Academic Validation
  2. Cole-Carpenter syndrome is caused by a heterozygous missense mutation in P4HB

Cole-Carpenter syndrome is caused by a heterozygous missense mutation in P4HB

  • Am J Hum Genet. 2015 Mar 5;96(3):425-31. doi: 10.1016/j.ajhg.2014.12.027.
Frank Rauch 1 Somayyeh Fahiminiya 2 Jacek Majewski 2 Jian Carrot-Zhang 2 Sergei Boudko 3 Francis Glorieux 4 John S Mort 4 Hans-Peter Bächinger 3 Pierre Moffatt 4
Affiliations

Affiliations

  • 1 Shriners Hospital for Children, Montréal, QC H3G 1A6, Canada. Electronic address: [email protected].
  • 2 Department of Human Genetics, McGill University and Génome Québec Innovation Centre, Montréal, QC H3A 1B1, Canada.
  • 3 Shriners Hospital for Children, Portland, OR 97239, USA.
  • 4 Shriners Hospital for Children, Montréal, QC H3G 1A6, Canada.
Abstract

Cole-Carpenter syndrome is a severe bone fragility disorder that is characterized by frequent fractures, craniosynostosis, ocular proptosis, hydrocephalus, and distinctive facial features. To identify the cause of Cole-Carpenter syndrome in the two individuals whose clinical results were presented in the original description of this disorder, we performed whole-exome sequencing of genomic DNA samples from both individuals. The two unrelated individuals had the same heterozygous missense mutation in exon 9 of P4HB (NM_000918.3: c.1178A>G [p.Tyr393Cys]), the gene that encodes protein disulfide isomerase (PDI). In one individual, the P4HB mutation had arisen de novo, whereas in the other the mutation was transmitted from the clinically unaffected father who was a mosaic carrier of the variant. The mutation was located in the C-terminal disulfide isomerase domain of PDI, sterically close to the enzymatic center, and affected disulfide isomerase activity in vitro. Skin fibroblasts showed signs of increased endoplasmic reticulum stress, but despite the reported importance of PDI for collagen type I production, the rate of collagen type I secretion appeared normal. In conclusion, Cole-Carpenter syndrome is caused by a specific de novo mutation in P4HB that impairs the disulfide isomerase activity of PDI.

Figures